RussellPachynskiMD
Oncology • Saint Louis, MOGenitourinary Oncology, Hematologic Oncology
Associate Professor of Medicine Division of Oncology
Dr. Pachynski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Summary
- I have experience and expertise in tumor immunology and immunotherapy in the GU malignancies, with a focus on prostate cancer. My lab studies leukocyte trafficking with a goal of favorable modulation in the context of the tumor microenvironment for therapeutic purposes.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2006 - 2011- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2003 - 2005
University of Wisconsin School of Medicine & Public HealthClass of 2003
Stanford UniversityB.S., Biology, 1990 - 1994
Certifications & Licensure
MO State Medical License 2014 - 2026
CA State Medical License 2004 - 2024
Awards, Honors, & Recognition
- Research Scholar Grant American Cancer Society, 2023
- Prostate Cancer Foundation Team Challenge Award 2016
- Kimmel Scholar Award 2016
- Join now to see all
Clinical Trials
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer Start of enrollment: 2018 Sep 14
Publications & Presentations
PubMed
- Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer.Pradeep S Chauhan, Irfan Alahi, Savar Sinha, Elisa M Ledet, Ryan Mueller
Clinical Cancer Research. 2025-01-06 - Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hem...Jason J Luke, Karen Gelmon, Lillian L Siu, Victor Moreno, Jayesh Desai
Clinical Cancer Research. 2024-12-13 - A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer.Randy F Sweis, Gurkamal S Chatta, Rohit K Jain, Helen Moon, Scott Edward Delacroix
Clinical Cancer Research. 2024-11-22
Press Mentions
Physician-Scientists Receive Scholar-Innovator AwardJuly 24th, 2024- Physician-Scientists Receive Scholar-Innovator AwardJune 10th, 2024
- Physician-Scientists Receive Scholar-Innovator AwardJune 7th, 2024
- Join now to see all
Professional Memberships
- Member
- Member
- Society for Immunotherapy of Cancer (SITC)Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
